191 related articles for article (PubMed ID: 32196006)
1. B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management.
Rogers BB
Clin J Oncol Nurs; 2020 Apr; 24(2):199-204. PubMed ID: 32196006
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine in the treatment of hematologic malignancies. Introduction.
Diehl V; Cheson BD
Semin Oncol; 2002 Aug; 29(4 Suppl 13):1-3. PubMed ID: 12170424
[No Abstract] [Full Text] [Related]
3. Targeted therapy for hematologic malignancies.
Kuriakose P
Cancer Control; 2005 Apr; 12(2):82-90. PubMed ID: 15855891
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies.
Crassini K; Gibson J
Intern Med J; 2024 Jan; 54(1):16-25. PubMed ID: 38066723
[TBL] [Abstract][Full Text] [Related]
5. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
Huang LW; Wong SW; Andreadis C; Olin RL
Curr Oncol Rep; 2019 Mar; 21(4):35. PubMed ID: 30848394
[TBL] [Abstract][Full Text] [Related]
6. Hematologic malignancies: new developments and future treatments.
Cheson BD
Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S; Sportelli P; Miskin HP; Purdom MA; Weiss MS; Fowler NH
Lancet Haematol; 2019 Feb; 6(2):e100-e109. PubMed ID: 30709431
[TBL] [Abstract][Full Text] [Related]
8. Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic Malignancies.
Knepper TC; Saller J; Walko CM
Oncology (Williston Park); 2017 Feb; 31(2):138-46. PubMed ID: 28205194
[TBL] [Abstract][Full Text] [Related]
9. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
10. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
[TBL] [Abstract][Full Text] [Related]
11. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
Rao AV; Schmader K
Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond.
Katz BZ; Herishanu Y
Leuk Lymphoma; 2014 May; 55(5):999-1006. PubMed ID: 23885836
[TBL] [Abstract][Full Text] [Related]
14. Applications of monoclonal antibodies for the treatment of hematological malignancies.
Migkou M; Dimopoulos MA; Gavriatopoulou M; Terpos E
Expert Opin Biol Ther; 2009 Feb; 9(2):207-20. PubMed ID: 19236251
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugates in hematologic malignancies.
Leslie LA; Younes A
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714472
[TBL] [Abstract][Full Text] [Related]
16. Old disease, new targets. Part-II, haematological malignancies.
Kumar S; Masood N; Adil SN
J Pak Med Assoc; 2009 Aug; 59(8):555-61. PubMed ID: 19757705
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
Ogasawara K; Newhall K; Maxwell SE; Dell'Aringa J; Komashko V; Kilavuz N; Delarue R; Czuczman M; Sternas L; Rose S; Beach CL; Novick S; Zhou S; Palmisano M; Li Y
Clin Pharmacokinet; 2020 Feb; 59(2):217-227. PubMed ID: 31332669
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic lymphocytic leukemia with alemtuzumab: a review for nurses.
Lynn A; Williams ML; Sickler J; Burgess S
Oncol Nurs Forum; 2003; 30(4):689-94. PubMed ID: 12861328
[TBL] [Abstract][Full Text] [Related]
19. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
Weingart O; Rehan FA; Schulz H; Naumann F; Knauel I; Bohlius CB; Engert A
J Natl Cancer Inst; 2007 Sep; 99(17):E1. PubMed ID: 17728205
[No Abstract] [Full Text] [Related]
20. Antiblastic treatment of haematological malignancies during pregnancy: a crucial decision.
Michieli M; Peccatori FA; Lleshi A; Del Pup L; Valente D; Rupolo M; Tirelli U; Berretta M
Int J Immunopathol Pharmacol; 2012; 25(2 Suppl):21S-32S. PubMed ID: 23092517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]